| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8231521 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
Patients with MCC treated with RTx have a high likelihood of obtaining in-field control. Doses of 50 to 55 Gy in 20 to 25 fractions are recommended. A minority of patients are cured, with many dying of systemic relapse. Lower dose fractionation schedules (e.g., 25 Gy in 5 fractions) may be considered in patients with a very poor performance status.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michael M.B.B.S., M.Med., M.D., F.R.A.N.Z.C.R., Matthew B.Sc., M.B.B.S., Val B.A., M.Stat., Michael M.B.B.S., F.R.A.N.Z.C.R.,